The Prostate Cancer Foundation (PCF) announced on July 10th the 19 recipients of its Young Investigator (YI) Awards. The awards supply each winner with three years of funding to assist the scientist in researching, developing and delivering therapies for prostate cancer that can be both life-extending and life-saving.
The PCF is the leading philanthropic organization dedicated to the acceleration and funding of prostate cancer research, with over $700 million in funding raised since its founding in 1993. Since 2007, $47 million was invested towards supporting 223 young investors, with $3.6 million invested in 2017 alone.
Chief science officer and executive vice president at PCF, Howard Soule, PhD, talked about the YI awards in a press release, saying that, “We are proud to support this year’s young investigators who are leading projects that will continue to help accelerate the breakthrough discoveries needed to not only further advance therapies, but ultimately defeat prostate cancer once and for all.”
The 19 recipients of the 2017 Young Investigator rewards are:
- Di Zhao, PhD, The University of Texas MD Anderson Cancer Center
- David VanderWeele, MD, PhD, National Cancer Institute
- Konrad Stopsack, MD, MPH, Memorial Sloan Kettering Cancer Center
- David Quigley, PhD, University of California, San Francisco
- Mark Preston, MD, MPH, Harvard: Brigham and Women’s Hospital
- Yashar Niknafs, PhD, University of Michigan
- Nicholas Nickols, MD, PhD, University of California, Los Angeles
- Ping Mu, PhD, Memorial Sloan Kettering Cancer Center
- Fatima Karzai, MD, National Cancer Institute
- Wouter Karthaus, PhD, Memorial Sloan Kettering Cancer Center
- Thomas Hope, MD, University of California, San Francisco
- Stefanie Hectors, PhD, Icahn School of Medicine at Mount Sinai Hospital
- Stephanie Harmon, PhD, National Cancer Institute
- Robert Flavell, MD, PhD, University of California, San Francisco
- Michael Cheng, MD, Memorial Sloan Kettering Cancer Center
- Elena Castro, MD, PhD, Spanish National Cancer Research Center
- Maria Carlo, MD, Memorial Sloan Kettering Cancer Center
- Michael Augello, PhD, Weill Cornell Medicine
- Sarah Amend, PhD, Johns Hopkins University
